Search - tctmd.com

Displaying 761 - 780 of 7606

Sort: Relevancy | Date

News Conference News ESC 2024

ESC’s 2024 CCS Guidelines Embrace New Data, Smooth Old Tensions

Michael O'Riordan

September 17, 2024

News Conference News ESC 2024

Endometriosis and CV Risk: Link Needs Further Attention and Research

Yael L. Maxwell

September 12, 2024

News Daily News

Tricuspid TEER Continues to Offer Benefits Through 3 Years: TRILUMINATE

Caitlin E. Cox

September 12, 2024

News Daily News

Statins Are Cost-effective in the Elderly

Michael O'Riordan

September 11, 2024

News Conference News ESC 2024

New ESC Guidelines Merge PAD, Aortic Diseases Into Single Document

Caitlin E. Cox

September 10, 2024

News Conference News ESC 2024

REC-CAGEFREE I: DCB Fails to Match Up to DES for De Novo CAD

Todd Neale

September 09, 2024

News Conference News ESC 2024

‘Unlocking’ Scaffold Matches DES in Wide Range of PCI Patients, Including ACS

Michael O'Riordan

September 09, 2024

News Conference News ESC 2024

New ESC Guidelines on BP and Hypertension Shift Treatment Targets Lower

Yael L. Maxwell

September 04, 2024

News Conference News ESC 2024

Balloon-Expandable TAVI Superior to SAVR in Women at 1 Year: RHEIA

Caitlin E. Cox

September 04, 2024

News Conference News ESC 2024

SENIOR-RITA Offers Rare Insights Into Best Care for Older NSTEMI Patients

Michael O'Riordan

September 02, 2024

News Conference News ESC 2024

SHAM-PVI: Catheter Ablation Improves Objective Measure of AF Burden

Todd Neale

September 02, 2024

News Conference News ESC 2024

MitraClip vs Surgery for Severe FMR? MATTERHORN Claims Noninferiority

Shelley Wood

September 01, 2024

News Conference News ESC 2024

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

Michael O'Riordan

September 01, 2024

News Opinion CV Team Dispatch

September 2024 Dispatch for the CV Team

L.A. McKeown

September 01, 2024

News Conference News ESC 2024

Getting to Cholesterol Goal Early After MI Lowers Risk of Recurrent Events

Michael O'Riordan

September 01, 2024

Presentation ESC 2024

Finerenone in Heart Failure and Chronic Kidney Disease with Type 2 Diabetes: the FINE-HEART Pooled Analysis of Cardiovascular, Kidney, and Mortality Outcomes

Presenter: Muthiah Vaduganathan

September 01, 2024

Presentation ESC 2024

Edoxaban-Based Long-Term Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Disease: The EPIC-CAD Randomized Clinical Trial

Presenter: Gi-Byoung Nam

September 01, 2024

News Conference News ESC 2024

Edoxaban Monotherapy Wins for AF and Stable Coronary Disease: EPIC-CAD

Todd Neale

September 01, 2024

News Conference News ESC 2024

NOTION-3: PCI Before TAVI Lowers MACE Risks in Patients With Significant CAD

Michael O'Riordan

September 01, 2024

News Conference News ESC 2024

Three Common Biomarkers Closely Tied to Women’s 30-Year Risk of CV Events

Caitlin E. Cox

August 31, 2024

Advertisement

ESC’s 2024 CCS Guidelines Embrace New Data, Smooth Old Tensions

Endometriosis and CV Risk: Link Needs Further Attention and Research

Tricuspid TEER Continues to Offer Benefits Through 3 Years: TRILUMINATE

Statins Are Cost-effective in the Elderly

New ESC Guidelines Merge PAD, Aortic Diseases Into Single Document

REC-CAGEFREE I: DCB Fails to Match Up to DES for De Novo CAD

‘Unlocking’ Scaffold Matches DES in Wide Range of PCI Patients, Including ACS

New ESC Guidelines on BP and Hypertension Shift Treatment Targets Lower

Balloon-Expandable TAVI Superior to SAVR in Women at 1 Year: RHEIA

SENIOR-RITA Offers Rare Insights Into Best Care for Older NSTEMI Patients

SHAM-PVI: Catheter Ablation Improves Objective Measure of AF Burden

MitraClip vs Surgery for Severe FMR? MATTERHORN Claims Noninferiority

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

September 2024 Dispatch for the CV Team

Getting to Cholesterol Goal Early After MI Lowers Risk of Recurrent Events

Finerenone in Heart Failure and Chronic Kidney Disease with Type 2 Diabetes: the FINE-HEART Pooled Analysis of Cardiovascular, Kidney, and Mortality Outcomes

Edoxaban-Based Long-Term Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Disease: The EPIC-CAD Randomized Clinical Trial

Edoxaban Monotherapy Wins for AF and Stable Coronary Disease: EPIC-CAD

NOTION-3: PCI Before TAVI Lowers MACE Risks in Patients With Significant CAD

Three Common Biomarkers Closely Tied to Women’s 30-Year Risk of CV Events

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content